ZYUS Life Sciences Corporation specializes in manufacturing cannabinoid-based therapeutics for both medical and recreational use. The company faces significant financial concerns, highlighted by a low gross margin of 35.8% and extremely negative EBITDA and net margins, indicating ongoing operational challenges. Additionally, the current and quick ratios of 0.04 and 0.03 suggest severe liquidity issues. While the market cap of $40.26M reflects potential, the overall financial health score of 16/100 raises red flags for investors.
Loading financial metrics...
Company has $202K in cash but burned $1.8M last quarter. At this burn rate, only 0.1 quarters of runway remain without additional financing.
Revenue fell 22.6% year-over-year from $483K to $374K. The decline has persisted for multiple quarters.
Gross profit margin declined from 28.2% to 1.3% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-19.5M over the last year, representing 5202.4% of revenue.
Debt of $23.8M is 118.0x the company's cash position of $202K.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)